Optaflu
- Generic Name
- Optaflu
Vaccine Responses in Patients With B Cell Malignancies
Phase 4
Recruiting
- Conditions
- Lymphoma
- Interventions
- Biological: Heplisav -BBiological: Pfizer-COVID-19 VaccineBiological: FluLavalDrug: AREXVY, ABRYSVO
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 500
- Registration Number
- NCT05170399
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
Phase 1
Completed
- Conditions
- InfluenzaSeasonal Influenza
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2025-04-27
- Target Recruit Count
- 63
- Registration Number
- NCT04896086
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
Phase 4
Recruiting
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 50
- Registration Number
- NCT04101838
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath